Bristol Myers Squibb presents transformative research in the treatment of genitourinary cancers at ASCO GU 2024.

The group presents the first presentation of results from the phase 3 CheckMate -67T trial with subcutaneous formulation of Opdivo (nivolumab and hyaluronidase).

Four-year data from CheckMate -9ER and unprecedented eight-year data from CheckMate -214 will confirm durable results with Opdivo-based combinations for patients with advanced renal cell carcinoma.

This is the first disclosure of clinical results from the Phase 1 trial with BMS-986365 (CC-94676), the company's first ligand-directed degrader of androgen receptors in solid tumors from its targeted protein degradation platform, in metastatic castration-resistant prostate cancer.

' These results highlight both the continued success of Opdivo-based combinations in metastatic disease and our contributions to the future of cancer treatment and research.'

We are particularly excited to share for the first time data showing the potential of our subcutaneous formulation of a proven agent and a novel mechanism of action in a difficult-to-treat tumor type - both of which could have a dramatic impact on existing standards of care and patient experience' said Samit Hirawat, M.D., Executive Vice President and Medical Director of Drug Development at Bristol Myers Squibb.


Copyright (c) 2024 CercleFinance.com. All rights reserved.